	US 11,701,324 B2
	Vaginal hydrogel for delivery of therapeutics
Marina Lee Gerton, Salt Lake City, UT (US); and Brenda K. Mann, Salt Lake City, UT (US)
Filed by Marina Lee Gerton, Salt Lake City, UT (US); and Brenda K. Mann, Salt Lake City, UT (US)
Filed on Feb. 19, 2021, as Appl. No. 17/179,854.
Application 17/179,854 is a division of application No. 16/233,102, filed on Dec. 27, 2018, granted, now 10,959,945.
Claims priority of provisional application 62/645,801, filed on Mar. 21, 2018.
Prior Publication US 2021/0169797 A1, Jun. 10, 2021
Int. Cl. A61K 9/06 (2006.01); A61K 9/00 (2006.01); A61K 47/38 (2006.01); A61K 47/32 (2006.01); A61K 31/4164 (2006.01); A61K 9/70 (2006.01); A61K 47/10 (2017.01); A61P 15/02 (2006.01)

CPC A61K 9/06 (2013.01) [A61K 9/0034 (2013.01); A61K 9/7015 (2013.01); A61K 31/4164 (2013.01); A61K 47/10 (2013.01); A61K 47/32 (2013.01); A61K 47/38 (2013.01); A61P 15/02 (2018.01)]

20 Claims

1. A crosslinked composition comprising:

a glycosaminoglycan comprising a plurality of thiol-reactive sites,

a molecule A comprising at least two thiol groups,

a mucoadhesive agent, and

a therapeutic agent having a solubility in water of less than about 1.0 mg/mL,

wherein the composition is dried by a process selected from air drying or lyophilization, and

wherein the glycosaminoglycan is crosslinked to the molecule A at a pH selected from a value between about 3.2 and about 5.0.